BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Lifeline BioTechnologies, Inc. (LBTN.PK) Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions


9/5/2012 9:52:32 AM

RENO, Nev., Sept. 4, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (OTC Market: LLBO) announces the award of US Patent #8,226,572 B2 for Methods for Collecting and Analyzing Thermal Data Based on Breast Surface Temperature to Determine Suspect Conditions.

"This Methods patent adds to our core intellectual property along with the device patent we received this past May and for our previously FDA approved 510(k) medical device" says Jim Holmes, Chairman/CEO. "Our basis for originally applying for the three software patents was as a result of the software technical work completed by world renowned pattern recognition specialists we engaged at Nanyang Technological University, Singapore. Once they had modified and improved our technology capabilities to achieve acceptable and competitive accuracy, sensitivity (false positive) and specificity (false negative) utilizing our patient data, we were convinced our processes were patentable. This novel and exciting technology holds the potential to change the way early breast tissue abnormalities and breast cancers are detected" concluded Holmes.

First Warning Systems, Lifeline Biotechnologies' exclusive licensee, is currently updating the patient data collection device and its interpretive software to complete the product package in preparation for market entry. First Warning is conducting a funding round. See firstwarningsystems.com/investors.html for more information.

About First Warning Systems

First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS' principal shareholder is Lifeline Biotechnologies, Inc. Lifeline has licensed FWS with the worldwide exclusive right for development, manufacturing, marketing and commercialization of its intellectual property. The product is a device and process that detects breast tissue abnormalities. Many of these tissue abnormalities will develop into breast diseases, some of which will be breast cancers. The FWS process does not involve compression or radiation and is noninvasive. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russian markets. See FWS' video, "Breast Cancer Tumor Progression" at www.firstwarningsystems.com/investors.html

About Lifeline Biotechnologies

Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV. LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer. Three "Proof of Concept" clinical trials of over 650 women have been completed and three patents (one hardware, two software) have been awarded. www.lbti.com.

Lifeline's efforts continue to have DTC remove the chill and allow trading to resume.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

For more information, contact: Jim Holmes, CEO 775-852-3222 Email: Jholmes@lbti.com

SOURCE Lifeline Biotechnologies, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->